Recruiting

Semaglutide

Sponsor:

University of Alberta

Code:

NCT07272837

Conditions

Type 2 Diabetes

Obesity

Semaglutide

GLP-1

Diabetes

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The aim of this study is to use advanced MRI scans to track changes in both muscle and fat in the body and heart over a 12-month period in individuals starting semaglutide. By doing so, we hope to gain a clearer understanding of how semaglutide affects muscle health and function. Our goal is to ensure the medication supports long-term well-being, particularly for people who may be at higher risk of muscle loss.

This study involves (3) in-person study visits. At each visit, participants will be asked to:

  • Undergo magnetic resonance imaging (MRI) while resting and during exercise to take pictures of their heart, abdomen, and legs.
  • Complete tests to assess balance, sit-to-stand, walking speed, and handgrip strength.
  • Complete questionnaires related to demographics, health information, physical activity, and nutrition.
  • Have a blood sample collected from a vein in your arm.
  • Have your blood levels assessed through three finger pricks.
  • Complete three days of food records.

Conditions

Type 2 Diabetes

Obesity

Semaglutide

GLP-1

Diabetes

Study ID

NCT07272837

Start date

May 15, 2026

Status verified date

Jul, 2026

Completion date

Apr 30, 2028

Anticipated

Primary completion date

Dec 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Adults 18-80 years of age
  • Starting semaglutide for type 2 diabetes or weight loss
  • Able to safely undergo an MRI scan (including meeting the physical requirements for MRI equipment)

Exclusion Criteria:

  • Current use of semaglutide for more than 2 weeks
  • Major recent heart issues or other severe health conditions
  • Concerns related to MRI use (including magnetic implants, pacemaker, severe claustrophobia)
  • Dependence on a mobility aid (unable to participate in exercise MRI)

Study Design

Enrollment

50 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Changes in skeletal and cardiac muscle mass [ Time Frame: 12 months ]

Central Contacts and Locations

Central contacts

Locations

Mazankowski Alberta Heart Institute

Recruiting

Edmonton, Alberta, Canada, T6G 0M9

Contacts

More Information

Sponsor

University of Alberta

Last update posted

Jul 17, 2026

Last verified

Jul, 2026

Keywords

  • Semaglutide
  • Type 2 Diabetes
  • Diabetes
  • Obesity
  • Body Composition
  • Muscle Mass
  • Skeletal Muscle Mass
  • Cardiac Muscle Mass
  • GLP-1 Receptor Agonist
  • GLP-1
  • MRI
  • Magnetic Resonance Imaging

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Alberta on 2026-07-17.